Israel Health Tax To Be Extended

30 June 1996

To help eliminate the NIS1 billion ($306 million) deficit in Israel's sick funds, collection of the new health tax is to be extended to non-salaried sources of income such as company dividends, and certain exemptions will be revoked. The Treasury believes the health tax revenues will be a chronic problem producing an annual deficit of around NIS1 billion for years to come.

The health tax was established in 1995 with the introduction of National Health Insurance. The NHI Law says the Treasury must clear any deficits resulting from collection of the tax revenues; this usually involves the transfer of money to the various sick funds. In June, the Parliamentary Finance Committee approved special funding of NIS81.4 million ($25 million) to the Meuhedet fund, within the terms of an agreement that by 1998, under an efficiency program, it will no longer be running a deficit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight